Medicines For Europe Pushes Industrial Policy Goals
Ahead Of European Council Meeting In Late March
Ahead of an upcoming European Council meeting covering the EU’s industrial policy and ongoing response to the COVID-19 pandemic, Medicines for Europe has set out what it sees as key policy objectives to consider.
You may also be interested in...
While the European off-patent industry has welcomed the latest update to the EU’s industrial strategy, including a detailed analysis of European dependencies on the global API manufacturing network, it has urged the European Commission to go further and provide “tailored actions” to bolster local manufacturing.
A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.